← back to search

Debyani Chakravarty

Dana-Farber Cancer Institute · US
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Genomics and Rare Diseases, and Genetic factors in colorectal cancer.
h-index
66
citations
67,281
works
274
NIH funding
primary concept
Biology
email

Recent publications

ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
Annals of Oncology 2025cited by 42position: middledoi
Abstract LB081: Carboxyamidotriazole orotate (CTO) with temozolomide (TMZ) for recurrent high-grade gliomas (rHGG) and in combination with TMZ/RT->TMZ in newly diagnosed glioblastoma (ndGBM): Long term follow-up of phase IB trial
Cancer Research 2025cited by 0position: middledoi
Automated real-world data integration improves cancer outcome prediction
Nature 2024cited by 140position: middledoi
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance
CA A Cancer Journal for Clinicians 2024cited by 57position: middledoi
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
Annals of Oncology 2024cited by 46position: middledoi
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia
Nature Genetics 2024cited by 21position: middledoi
Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
JAMA Oncology 2024cited by 19position: middledoi
Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer
Cell 2024cited by 17position: middledoi
Precision Oncology: 2024 in Review
Cancer Discovery 2024cited by 14position: lastdoi
Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications
Cancer Discovery 2023cited by 47position: middledoi
Precision Oncology: 2023 in Review
Cancer Discovery 2023cited by 36position: lastdoi
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
Nature Communications 2023cited by 27position: middledoi
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Cell 2022cited by 637position: middledoi
Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)
Genetics in Medicine 2022cited by 229position: middledoi
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Nature Medicine 2022cited by 178position: middledoi
Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants
Nature Biotechnology 2022cited by 128position: middledoi
Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Clinical Cancer Research 2022cited by 44position: middledoi
AKT mutant allele-specific activation dictates pharmacologic sensitivities
Nature Communications 2022cited by 35position: middledoi
GA4GH: International policies and standards for data sharing across genomic research and healthcare
Cell Genomics 2021cited by 290position: middledoi
OncoTree: A Cancer Classification System for Precision Oncology
JCO Clinical Cancer Informatics 2021cited by 145position: middledoi
A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
Nature Genetics 2020cited by 175position: middledoi
The Evolutionary Origins of Recurrent Pancreatic Cancer
Cancer Discovery 2020cited by 127position: middledoi
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Cell 2018cited by 3,906position: middledoi
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Cell 2018cited by 3,331position: middledoi
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Cell 2018cited by 2,670position: middledoi
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Cell 2018cited by 2,331position: middledoi
Genomic and Functional Approaches to Understanding Cancer Aneuploidy
Cancer Cell 2018cited by 1,182position: middledoi
Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images
Cell Reports 2018cited by 1,045position: middledoi
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients
Cancer Cell 2018cited by 954position: middledoi
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines
Cell Systems 2018cited by 936position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Eileen M. O’Reilly · Erasmus MC Cancer Institute3 papers (2020–2024) · 2 papers (2023–2024)Clare Turnbull · Institute for Research in Schools2 papers (2024–2024)Nikolaus Schultz · Cancer Clinic2 papers (2018–2022)Michael F. Berger · Memorial Sloan Kettering Cancer Center2 papers (2022–2023)Joaquı́n Mateo · Departamento de Educación2 papers (2018–2024)Britta Weigelt · New York University2 papers (2023–2024)Barry S. Taylor · University of Maryland, Baltimore2 papers (2020–2022)C. Benedikt Westphalen · LMU Klinikum2 papers (2024–2024)Alexander Drilon · Université Grenoble Alpes2 papers (2023–2024)Cameron Brennan · Center for Neuro-Oncology2 papers (2017–2025)Ritika Kundra · University of Duisburg-Essen1 papers (2022–2022)Alexia Iasonos · Repsol (Spain)1 papers (2023–2023)Ralph H. Hruban · Occupational Cancer Research Centre1 papers (2020–2020)Kenneth Offit · University of Virginia1 papers (2018–2018)Fabrice André · Institut Gustave Roussy1 papers (2024–2024)Nadeem R. Abu‐Rustum · Memorial Sloan Kettering Cancer Center1 papers (2023–2023)Nicola Normanno · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori1 papers (2024–2024)Giuseppe Curigliano · Istituti di Ricovero e Cura a Carattere Scientifico1 papers (2024–2024) · 1 papers (2024–2024)